Managing Papulopustular Rosacea With Once-daily ORACEA® (doxycycline, USP) 40 mg* Capsules

Understanding the Burden of Rosacea

Management Approach and Goals of Therapy

ORACEA® (doxycycline, USP) 40 mg* Capsules:
Efficacy and Tolerability vs Placebo

Results From a Clinical Study: ORACEA®
(doxycycline, USP) 40 mg Capsules vs Doxycycline 100 mg

Antibiotic Stewardship With ORACEA®
(doxycycline, USP) 40 mg* Capsules

Indication and Important
Safety Information

See full Prescribing Information Click Here

Important Safety Information and Indication

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

*30 mg immediate release & 10 mg delayed release beads

Meet the Speakers

Joseph Mikhael headshot

Hilary E. Baldwin, MD, FAAD

Medical Director
Acne Treatment & Research Center
Brooklyn, NY

Clinical Associate Professor
Rutgers Robert Wood Johnson Medical Center
New Brunswick, NJ

Jeffrey S. Fromowitz, MD, FAAD

Jeffrey S. Fromowitz, MD, FAAD

Managing Partner and Medical Director
Boca Raton, FL

Adjunct Assistant Professor of Medicine
Florida Atlantic University College of Medicine
Boca Raton, FL

The production of this Dermatology Times® video was supported by Galderma Laboratories, L.P. The speakers are paid
consultants of Galderma Laboratories, L.P.

© 2020 Galderma Laboratories, L.P. United States, All Rights Reserved. All trademarks are the property of their respective